VivoSeq
Infectious Disease

Viral Hepatitis

3

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Viral Hepatitis is an early-stage landscape with 3 programs across 2 companies. The most active players are Vir Biotechnology, Inc., Gilead. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vir Biotechnology, Inc.

2 programs

Phase 3Gilead logo

Gilead

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 33

Tobevibart

Vir Biotechnology, Inc.

Elebsiran

Vir Biotechnology, Inc.

Bulevirtide

Gilead

Approved
No programs

Analysis

Modality Breakdown

3programs
Small molecule133%
Peptide133%
RNA therapy133%

Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)
Active, not recruiting·VVir Biotechnology, Inc.·Phase 3·NCT07128550·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)